Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].
作者信息
Yim Sun Young, Lee Sung Hwan, Baek Seung-Woo, Sohn Bohwa, Jeong Yun Seong, Kang Sang-Hee, Park Kena, Park Hyewon, Lee Sunyoung S, Kaseb Ahmed O, Park Young Nyun, Leem Sun-Hee, Curran Michael A, Kim Ji Hoon, Lee Ju-Seog
机构信息
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):669-670. doi: 10.3350/cmh.2024.0333e. Epub 2025 Feb 27.
Abstract
摘要
相似文献
1
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].《肝细胞癌中预测阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解》勘误 [《临床分子肝病学》2024年；30:807 - 823]
Clin Mol Hepatol. 2025 Apr;31(2):669-670. doi: 10.3350/cmh.2024.0333e. Epub 2025 Feb 27.
2
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
3
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".预测晚期肝细胞癌组织中联合免疫治疗反应的转录组特征：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
4
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
5
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".致编辑的信：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
6
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".对关于“预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信的回复
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
7
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
8
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
9
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.阿替利珠单抗联合贝伐单抗用于不符合IMbrave150纳入标准的不可切除肝细胞癌患者的早期反应及安全性
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
10
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
Zotero 插件